McKesson Corporation (MCK)Rep. Ritchie John Torres (NY15) disclosed a purchase $1K–$15K
Rep. Ritchie John Torres (NY15) disclosed a purchase of McKesson Corporation in the $1K–$15K range.
- $1,001–$15,000
- Reported range · official band, not an exact amount
- 547 days
- Disclosure lag
- Traded
- Jan 7, 2025
- Disclosed
- Jul 8, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 9, 2024InsiderOfficer sold ~$349K of MCK shares in the open market
- Jan 2, 2025InsiderOfficer sold ~$332K of MCK shares in the open market
What came next
- Jan 15, 2025Congress · 1 personMembers of Congress: 2 purchases
- Jan 24, 2025CongressDisclosed sale of MCK — reported range $1,001 - $15,000
- Feb 12, 2025InsiderOfficer sold ~$115K of MCK shares in the open market
- Feb 14, 2025InsiderCEO sold ~$5.38M of MCK shares in the open market
- Feb 21, 2025InsiderCEO sold ~$5.36M of MCK shares in the open market
- Feb 25, 2025InsiderOfficer sold ~$189K of MCK shares in the open market
- Feb 28, 2025InsiderCEO sold ~$5.59M of MCK shares in the open market
- Mar 4, 2025CongressDisclosed purchase of MCK — reported range $1,001 - $15,000
- Mar 6, 2025InsiderCEO sold ~$5.68M of MCK shares in the open market
- Apr 24, 2025FDARecall: SEKISUI DIAGNOSTICS LLC SERUM HCG OSOMGENZME CONTROL SET.
- Apr 24, 2025FDARecall: ABBOTT POINT OF CARE TEST CREA I-STAT (25/BX) ABBTPT CARTRIDGE.
- Apr 24, 2025FDARecall: ORTHO CLINICAL DIAGNOSTICS INC ANTI-B BIOCLONE 10ML3X10ML.
- Apr 24, 2025FDARecall: ORTHO CLINICAL DIAGNOSTICS INC VITROS BUN (60/CR 5CR/PK) ORCLNL REAGENT.
- Apr 24, 2025FDARecall: ABBOTT DIAGNOSTICS ARCH AUSAB ANTI-HBS (100/EA) REAGENT.
- Apr 24, 2025FDARecall: ABBOTT DIAGNOSTICS ARCHITECT PROGESTERONE (100TESTS) REAGENT.
- Apr 24, 2025FDARecall: ABBOTT DIAGNOSTICS ARCHITECT FREE T4ABBDIA CALIBRATOR.
- Apr 24, 2025FDARecall: ABBOTT DIAGNOSTICS ARC ANTI-TPO ASSAY 100TST B REAGENT.
- Apr 24, 2025FDARecall: ABBOTT RAPID DX N AMERICA LLC, TEST CHOLESTEC LDXLIPID PROFILE (10/BX 50BX/CS) CASSETTES.
- Apr 24, 2025FDARecall: HEMOCUE INC GLUC AQUEOUS 1HI/LO HEMCUE CONTROL KIT.
- Apr 24, 2025FDARecall: ORTHO CLINICAL DIAGNOSTICS INC VITROS CALCIUM (L-SEQUESTER) (300/PK) REAGENT.
How to read House Clerk periodic transaction report
The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.
Full guide: What is the STOCK Act?
What else is on file for McKesson Corporation
For McKesson Corporation, OQRO holds 2 insider filings (SEC Form 4 or Form 144), 2 Congress trade reports, 47 fund holdings reports (13F) and 3 federal contract awards dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its MCK page.
Other recent filings by Rep. Ritchie John Torres (NY15)
- House Clerk periodic transaction report at AbbVie (ABBV)Aug 20, 2025
- House Clerk periodic transaction report at PepsiCo (PEP)Aug 20, 2025
- House Clerk periodic transaction report at AbbVie (ABBV)Aug 20, 2025
- House Clerk periodic transaction report at Alexandria Real Estate Equities (ARE)Aug 20, 2025
- House Clerk periodic transaction report at Blackstone Inc. (BX)Aug 20, 2025
The full history of Rep. Ritchie John Torres (NY15) is on the profile page.
How this filing works
Other disclosures at McKesson Corporation
- USAspending.gov award recordOct 5, 2026
- SEC Form 4Sep 10, 2026
- USAspending.gov award recordSep 4, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
- SEC Form 13F-HRAug 14, 2026
Everything OQRO holds on this company is on its MCK page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
